Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical Cancer

Inclusion Criteria: * Women over 18 years old * Cervical Cancer at IIIA, IIIB y IIIC1 FIGO´s clinical stages * Histology: squamous, adenosquamous or adenocarcinoma * No previous treatment * No distance metastases, discard by Positron Emission Tomography (PET)/CT * Functional State ECOG (Eastern Cooperative Oncology Group) 0-2 * Complete Blood count obtained at least 14 days before admission to the study with adequate bone marrow function defined as: * Absolute neutrophil count ≥ 1,500 cell/mm3 * Platelets ≥ 100,000 cell/mm3 * Hemoglobin ≥ 10.0 g/dl * Leukocyte count ≥ 4000 cell/mm3 * Adequate Renal Function defined as: * Serum Creatinine ≤ 1.5 mg/dl within 14 days before admission to the study * Patients with HIV infection (human immunodeficiency virus) must have a CD4 cell count ≥ 350 cells / mm3 measured within 14 days prior to study entry (no HIV test is required) * The patient must understand the protocol and provide the specific informed consent of the study before admission * Negative pregnancy test Exclusion Criteria: * Patients who had chemotherapeutic, surgical and/or radiotherapy treatment for female reproductive tract pathologies * Previous invasive neoplasia (except non-melanoma skin cancer) unless there is complete remission of the disease of 3 years minimum (For example, breast cancer or oral cavity cancer) * Previous systemic chemotherapy for current cervical cancer, take into account that prior chemotherapy for a different cancer is accepted, as long as they have been at least 3 years * Severe active or non-controlled co-morbidities, defined as: * Unstable angina and/or congestive heart failure that required hospitalization in the last 6 months. * Transmural myocardial infarction in the last 6 months. * Acute bacterial or fungal infection requiring intravenous antibiotics at the beginning of the study. * Chronic obstructive pulmonary disease exacerbation or another respiratory disease that requires hospitalization or that contraindicates the trial therapy at the time of admission. * Crohn's disease or ulcerative colitis. * Prior allergic reaction to cisplatin or other drugs based on platinum. * Other factors that contraindicate experimental therapy.